The progress made in liver disease research to date presents an opportunity for further advancements in the near future.

That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant ...

Just a few months after announcing a plan to separate its drug and cell therapy businesses into two separate companies, ...

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

Netherlands biotech Azafaros is poised to start phase 3 trials of its lead drug for a trio of rare lysosomal storage ...

Improving Global Access to Life-Changing Therapeutics... Following the successful Boston and London meetings, the ...

The difference comes from the sourcing of raw materials and the functioning – and even nature – of supply chains. Because the ...

Moreover, Downing Street has indicated that the UK will receive "preferential treatment in any further tariffs imposed" as ...

That is according to the chief executive of the American Association for the Advancement of Science (AAAS), Sudip Parikh, who ...

President Donald Trump has signed an executive order that he claims will cut prescription drug prices supplied to the US to ...